Lung Cancer Non-small Cell Stage IV Clinical Trial
Official title:
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Pemetrexed vs Placebo Combined With Carboplatin and Pemetrexed as First-line Therapy in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed as first-line therapy in patients with EGFR and ALK wild type metastatic nonsquamous non-small cell lung cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03692442 -
Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
|
||
| Recruiting |
NCT03769103 -
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT06463171 -
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02129699 -
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
|
Phase 3 | |
| Recruiting |
NCT05127382 -
Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer
|
||
| Completed |
NCT03866993 -
A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT04184921 -
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
|